Oxidative Stress in Autoimmune Rheumatic Diseases
Summary
NIH National Library of Medicine registered an observational study (NCT07536529) examining oxidative stress markers in autoimmune rheumatic diseases including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The study measures blood and tissue redox status to understand free radical impact on biomolecules in inflammatory joint disease patients. This registry entry applies to clinical investigators and healthcare providers involved in the study.
What changed
NIH National Library of Medicine registered a new observational study on ClinicalTrials.gov to examine oxidative stress markers in patients with autoimmune rheumatic diseases including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and systemic lupus erythematosus. The study investigates the disturbance of blood and tissue redox status due to excessive free radical production and its impact on biomolecules including proteins, lipids, and DNA. This registry entry provides transparency on ongoing clinical research but does not create compliance obligations for any regulated parties. Healthcare providers and clinical investigators conducting the study must follow standard research protocols and IRB requirements, while other entities are not affected by this registration notice.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Oxidative Stress in Autoimmune Rheumatic Diseases
Observational NCT07536529 Kind: OBSERVATIONAL Apr 17, 2026
Abstract
Rheumatic diseases constitute a group of non-communicable diseases characterized by chronic inflammation. The most common autoimmune rheumatic diseases (ARDs) are rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, myositis, Sjogren's syndrome and systemic scleroderma. These autoimmune disorders lead to joint destruction and adversely influence the human body systemically. One of their characteristics is comorbidity, since patients usually suffer also from other pathologies such as cardiovascular diseases and obesity. In addition, their treatment requires a combination of both biological and conventional pharmaceutical interventions as well as other parameters such as physical activity programs, nutrition, and the use of smart electronic devices. Therefore, the ARDs burden health systems worldwide. Apart from the physiological manifestations of ARDs, specific changes are observed at the cellular and molecular level. A common biochemical/molecular symptom of these diseases is oxidative stress. This condition leads to the disturbance of blood and tissue redox status due to the excessive production of free radicals. Given that free radicals are highly reactive moieties with strong oxidative capacity against biomolecules (i.e., proteins, lipids, DNA), they compromise the efficacy of the intrinsic antioxidant mechanisms and, finally, induce the disruption of redox homeostasis. However, there is no sufficient data linking the levels of redox status of patien...
Conditions: Inflammatory Joint Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS)
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.